Skip to main content
. 2013 Feb;2(1):40–49. doi: 10.3978/j.issn.2218-6751.2012.12.05

Table 2. Main criticisms reported with first-generation EGFR-TKIs.

No response in near 30% of NSCLC with classical exon 19-21 mutation
No clear benefit in presence of uncommon mutations
Toxicity
No patient is cured: median duration of response 9-12 months
Lack of efficacy in presence of “acquired” T790M mutation